The 4th of February is the day to raise awareness of cancer worldwide.

Tiefenbacher Group joins the initiative led by the Union for International Cancer Control (UICC) to remind people that cancer has a global impact of around 20 million new cases each year and is a major public health challenge.

The new World Cancer Day campaign 2025-27 “United by Unique” places people at the center of care and will explore new ways of making a difference. In the fight against this disease, Tiefenbacher Group is committed to providing better and more affordable medicines to cancer patients around the world.

Tiefenbacher Group Pharmaceuticals

Thanks to our exceptional cancer pharmaceuticals, such as Abiraterone, Enzalutamide, Letrozole, Olaparib, Palbociclib, Regorafenib, Temozolomide, and Venetoclax, we have made significant progress towards our objective of providing more affordable medicines. Additionally, we can offer better therapies for patients through differentiated and innovative product solutions, including reducing the pill burden with improved posology, additional strengths, and suitable fixed-dose combinations. Moreover, we ensure better treatment compliance through personalized therapies by integrating medicines with advanced e-health solutions.

Our new state-of-the-art facilities in Hyderabad, India, will enable us to launch a sustainable pipeline of high potent cancer drugs which are planned to be developed and manufactured in-house.

Tiefenbacher Group joins the initiative led by the Union for International Cancer Control (UICC) to remind people that cancer has a global impact of around 20 million new cases each year and is a major public health challenge.
About Tiefenbacher Group – Pioneering Healthcare since 1963

Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health solutions. The purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.

For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on:  www.tiefenbachergroup.com